As such, application of a HSP90 inhibitors as therapeutic drugs for PAH treatment, might affect other pathological and physiological processes, such as oxidative stress or neoangiogenesis [14, 15]. The gene discussed is HSP90AA1; the disease is pulmonary arterial hypertension.